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Cancer therapyIn this review, the evidence for a role of ﬁbroblast growth factor receptor (FGFR) mediated signalling in car-
cinogenesis are considered and relevant underlying mechanisms highlighted. FGF signalling mediated by
FGFR follows a classic receptor tyrosine kinase signalling pathway and its deregulation at various points of
its cascade could result in malignancy. Here we review the accumulating reports that revealed the association
of FGF/FGFRs to various types of cancer at a genetic level, along with in vitro and in vivo evidences available so
far, which indicates the functional involvement of FGF signalling in tumour formation and progression. An in-
creasing number of drugs against the FGF pathways is currently in clinical testing. We will discuss the strat-
egies for future FGF research in cancer and translational approaches.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Carcinogenesis follows the stepwise progression of normal benign
cells to cancer cells that have acquired abilities in independent growth,
to evade anti-apoptotic signals, to promote angiogenesis, and to invade
and metastasise to distant organs [1]. This progression can be charac-
terised bymultiple genemutations, often happening in a speciﬁc tempo-
ral fashion. Such mutations may include activating mutations, gene
ampliﬁcations and overexpression of oncogenes, or inactivating muta-
tions and epigenetic silencing of tumour suppressors. However, simple
association of themutations is not sufﬁcient in providing themechanism
underlying cancer progression. Themutations may be ‘passenger’muta-
tions, and may not always be the critical ‘driver’ events that provide the
malignant cells survival advantage and the ability for clonal expansion.
Receptor tyrosine kinases (RTKs) consist of 20 subfamilies in
humans, all of which share a common structure consisting of extracellu-
lar ligand-binding region, a single-pass transmembrane domain and an
intracellular tyrosine kinase domain [2]. Binding of a growth factor to
the ligand-binding domain results in RTK activation and initiation of in-
tracellular signalling cascades, which lead to cellular effects.
Fibroblast growth factor (FGF) signalling mediated by its high-
afﬁnity tyrosine kinase receptors, FGF receptors (FGFRs) is known to
instigate a range of responses in different cell types, and is regulated
by its complex expression patterns and binding speciﬁcity of the FGF
ligands and receptors as well as their isoforms [3,4].cer Research, Garscube Estate,
.: +44 1413308695; fax: +44
ng).
l rights reserved.FGF signalling is probably most well-known for its regulatory
function in multiple developmental processes including mesodermal
patterning in the embryo [5] and subsequent formation of numerous
organ systems [6]. In adult, it contributes to tissue homeostasis, as
well as tissue repair, angiogenesis and inﬂammation [3,4,7]. Given
such a plethora of biological effects that FGF signalling lead to, it
may not be surprising that its deregulation can have signiﬁcant con-
sequences in carcinogenesis.
2. FGF signalling via high-afﬁnity receptor FGFR
2.1. FGF
The prototypemembers of the FGF family, namely FGF1 (acidic FGF)
and FGF2 (basic FGF), were isolated as mitogens from the bovine brain
tissue in the 1970s [8]. Since then a plethora of other cellular functions
have been identiﬁed in a variety of cell types and organs, which include
cell survival, differentiation, and migration, as well as angiogenesis [9].
Twenty-two FGFs have been identiﬁed in mammals. Most of the FGFs
are secreted glycoproteins, however, four members (FGF11–14) do
not function as FGF ligands. There is no human equivalent of mouse
FGF15; there is no human FGF19 in mice. Most FGF ligands function in
a classic autocrine and/or paracrine fashion, with an exception of
FGF19, 21 and 23, whichwere identiﬁed as hormones capable of diffus-
ing into the circulation (FGF19 subfamily) [10–15].
FGFs are subjected to many splicing events that affect their func-
tion. Intriguingly, some FGFs have been identiﬁed as having a nuclear
function [9,16], instigating a different downstream effect to the clas-
sic RTK pathways. Apart from FGF1 and FGF2, which are exported
from cells via undeﬁned mechanism(s), the remaining FGFs utilise a
Table 1
Summary of FGF receptor speciﬁcity
FGFRs can either express the IIIb or IIIc exon, which inﬂuences FGF ligand speciﬁcity.
FGFR IIIb subtype FGFR IIIc subtype
FGF7 subfamily (3,7,10,22)
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glycosaminoglycan side-chains of cell surface proteoglycans, thus
they are normally trapped on the surface of the secretory cell or near-
by cells, augmenting their action as short-range signalling molecules
and providing a biologic reservoir for FGFs [17].
FGFs also bind to low-afﬁnity receptors present on most cells, the
HSPGs (heparin sulphate proteoglycans) [18–20]. HSPGs consist of a
proteoglycan core that binds 2 or 3 linear polysaccharides (heparin sul-
phate chains). The FGFs bind to the negatively charged polysaccharides
through electrostatic interactions. HSPGsmay protect ligands fromdeg-
radations, as well as stabilising the FGF ligand–receptor complex by
forming a ternary complex with FGFR.
Members of the FGF family are divided into subfamilies according
to receptor speciﬁcity (Table 1) [21–23]. FGF-7, 10, and 22 are more
closely related to each other by sequence homology than to the
other FGFs, and, along with FGF3, form the FGF7 subfamily. Similarly,
FGF-8, 17, and 18 represent a second subfamily sharing similar activ-
ities to each other, and is referred to as the FGF8 subfamily. Finally,
the FGF9 subfamily (FGF-9, 16, and 20) shares a similar structure pro-
ﬁle to that of FGF9.
2.2. FGFR
FGFRs are transmembrane tyrosine kinase receptors that belong to
the immunoglobulin (Ig) superfamily [24] (Fig. 1). Activation by their
respective high-afﬁnity FGF ligands results in kinase activation that





































Fig. 1. Fibroblast growth factor receptor (FGFR) structureFGFR possesses three extracellular (
a split, cytoplasmic (CP) tyrosine kinase domain (TK1 and TK2). The basic structure of the
FGFs and one heparin sulphate proteoglycan (HSPG) chain. The second and third Ig domai
HSPGs. The major tyrosine sites of phosphorylation of FGFR1–4 are shown in the table.the FGFR family consists of 4 receptor genes encoding closely related
transmembrane RTKs [24], namely FGFR1 to FGFR4. Each FGFR mono-
mer consists of an extracellular domain that includes the ligand-
binding site, two or three Ig loops that arise by alternative splicing,
an acidic box, a transmembrane domain, and a split tyrosine kinase
domain (Fig. 1). The ﬁrst Ig-like domain is postulated to play a role
in receptor auto-inhibition [25]. Alternative splicing of the third Ig-
like domain occurs in FGFR1–3 and inﬂuence the selection of the sec-
ond half of the third Ig like domain, generating the IIIb or IIIc isoform
of the receptor. The second and third Ig-like domains of the receptors
are sufﬁcient for FGF ligand binding and contribute to the diversity of
preferences in the ligand binging by each FGFR subtypes and isoforms
(Table 1)[21,26].
The expression of distinct (different) FGFR splice forms can be ob-
served in a tissue (or cell lineage) speciﬁc pattern. The IIIc isoform is
usually expressed inmesenchymal tissuewhile the IIIb isoform ismost-
ly detected in epithelial cells, particularly during development stages.
Interestingly, the ligands for epithelial receptors are often expressed
mesenchymal tissue and vice versa. This provides the basis for a para-
crine signallingmechanism, providing ameans for delicate homeostasis
between epithelial and mesenchymal tissues. Abnormality of this para-
crine signalling interaction between the epithelium and the mesen-
chyme may signiﬁcantly contribute to carcinogenesis [17].
2.3. Downstream signalling
Binding of FGFs to FGFRs induces receptor dimerization, leading to
conformational changes within the FGFR structure, thus enabling
trans-phosphorylation of tyrosines in the intracellular part of the re-
ceptor, including the kinase domain and the C-terminus [9,27].
There are 7 autophosphorylation sites in FGFR1, Y463 (juxtamem-
brane), Y583/Y585 (kinase insert), Y653/Y654 (the activation loop),
Y730 (kinase domain) and Y766 (C-terminal tail) [28,29]. Recent
studies using crystallography and cultured cells provided a renewed
insight into the activation process of FGFR kinase that occurs in
three sequential steps [30–32]. Firstly, transphosphorylation of the
tyrosine in the activation loop, Y653 in FGFR1, potently activates the
kinase by 50–100 fold. Secondly, the tyrosines in the juxtamembrane
region Y463, kinase insert Y583/Y585, and in the C-terminal tail,R
FG
F HSPG
FGFR1 FGFR2 FGFR3 FGFR4
Y463 Y466
Y583/585 Y586/588 Y577
Y653/654 Y656/657 Y647/648 Y624/64
3
Y730 Y733 Y724 Y719
Y766 Y724 Y760 Y754
Y776 Y719 Y754 Y764
EC) immunoglobulin-like domains (IgI–III), a single transmembrane domain (TM), and
ﬁbroblast growth factor (FGF)–FGFR complex consists of two receptor molecules, two
ns form the ligand-binding pocket and have distinct domains that bind both FGFs abs
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for various downstream proteins (see below for the examples). Final-
ly, the phosphorylation of Y654 in the activation loop activates the ki-
nase activity further by 10-fold.
Kinase domains of the four FGFRs are relatively well-conserved
(75–92% homology) with the closest homology between FGFR1 and
FGFR2 and the biggest difference between FGFR1 and FGFR4 [33].
Most of the 7 autophosphorylation sites, as well as the additional C-
terminal Y776 tyrosine, are conserved among the four FGFRs. However,
FGFR3 lacks tyrosine residue equivalent of juxtamembrane Y463 and ki-
nase insert Y585 in FGFR1, and FGFR4 lacks Y463, Y583/Y585 [29,34].
These differences in tyrosine phosphorylation proﬁle among FGFRs
may underlie a difference in the overall kinase activity and/or down-
stream signalling pathways, and all together, may deﬁne speciﬁc effects
mediated by each FGFR (Fig. 2).
Phosphorylated tyrosine residues function as docking sites for vari-
ous adaptor proteins [27]. Some of the adaptor proteins are phosphory-
lated directly by FGFR [27]. For example, upon phosphorylation the C-
terminal Y766 binds PLCγ [28] and Shb [35], which leads to recruitment
of FRS2 (see below). The binding of the docking proteins to FGFRs leads
to activation of multiple signal transduction pathways, including the
four main downstream pathways, Ras–Raf–MapK, PI3K–Akt, Stats, and
PLCγ [3,27].
Some of the main adaptor proteins include:
• FGFR substrate 2 (FRS2) — an adaptor/scaffold protein. FRS2 is par-
ticularly speciﬁc to FGFRs, although it can bind to other RTKs such
as neurotrophic tyrosine kinase receptor type 1 (NTRK1), RET and
anaplastic lymphoma kinase (ALK) [36]. It is constitutively associat-
ed with the juxtamembrane domain of the FGFR through its
phospho-tyrosine binding (PTB) domains. Several tyrosine residues
of FRS2 phosphorylated by the activated FGFR kinase serve as dock-
ing sites for proteins such as SOS, GRB2 and GAB1, allowing assem-
bly of signalling complexes that promote activation of Ras/Raf/




































































Fig. 2. Intracellular signalling cascades downstream of FGFRs.FGFR phosphorylation trigger
activated protein kinase kinase (MEK)–extracellular regulated kinase (ERK) pathway. In vi
those that involve the SRC-homology-2-domain-containing (SHC), growth factor receptor-b
80K-H (a protein kinase C substrate), GRB2, pp66 and SOS adaptor proteins. Alternatively, ph
way. Lastly, the activated FGFR can directly or indirectly (through Janus-family kinases (JAK
tivated FGFR can also interact directly with proline-rich tyrosine kinase 2 (PYK2), leading t
receptor tyrosine kinases, triggers similar signalling pathways.Colours refer to cellular loca• Phospholipase Cγ (PLCγ) — the Src homology 2 (SH2) domain of
PLCγ binds to FGFR at its auto-phosphorylated tyrosine in the
COOH-terminal tail (Y766 in FGFR1), resulting in phosphorylation
and activation of PLCγ [37]. This triggers the release of intracellular
calcium to activate calcium-dependent members of the protein ki-
nase C (PKC) family. This could also induce MAPK signalling via
phosphorylation of Raf.
Other pathways are also activated by FGFR signalling in a context de-
pendent manner. These include Shb (src homology 2 domain-
containing transforming protein B), Src kinase, p38 MAPK, Jun-N-
terminal kinase pathways, STATs (signal transducers and activators of
transcription), Crk and RSK (ribosomal S6 protein kinase). In particular,
STATs and RSK have demonstrated oncogenic properties in vitro
[3,38,39].
FGFR signalling is also negatively regulated, mediated by several
regulator proteins such as MAPK phosphatase 2 (MKP3) [40], the Spro-
uty (SPRY) proteins [41,42] and “similar expression to FGF” (Sef) family
members [43,44]. They act to modulate receptor signalling at several
points in the signal transduction cascade. MKP3 acts to dephosphory-
late ERK1 and ERK2 to attenuate MAPK signalling [40]. In contrast,
SPRY proteins either compete with GRB2 in a dominant negative fash-
ion, preventing SOS-mediated RAS activation, or directly bind to RAF,
leading to a block of MAPK signalling [41,42]. The transmembrane
form of Sef is capable of directly inhibiting FGFRs whilst both the trans-
membrane form and a cytoplasmic speciﬁc splice variant of Sef can pre-
vent phosphorylation of ERK [44,45]. FGF signalling is also negatively
regulated by the endocytosis of FGFR proteins, followed by their degra-
dation in lysosomes [27]. This is thought to be partially under the con-
trol of Cbl [46,47].
3. FGFR in cancer
A large amount of evidence now indicates that alteration of FGF


















s several signalling cascades, the most predominant of which is the RAS–RAF–mitogen
tro evidence indicates that two signalling complexes mediate this activation pathway:
ound protein 2 (GRB2) and son of sevenless (SOS) adaptor proteins and those involving
osphorylated FGFR can activate the phosphatidylinositol 3-kinase (PI3K) and AKT path-
s)) trigger the signal transducer and activator of transcription (STAT) pathway. The ac-
o STAT pathway activation. Notably, mutational activation of HRAS, a central target of
lisation (blue = membranous, green = cytoplasmic and red = nuclear).
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model and clinical materials. Below, we discuss the originating muta-
tional events at the gene level and the corresponding consequence in
tumour formation and progressions reported so far (Table 2).
3.1. Chromosomal translocations
Chromosomal translocations can lead to an expression of fusion
proteins with potent oncogenic function. The strongest evidence of
the involvement of FGF signalling in cancer has come from haemato-
logical malignancies, where FGFR chromosomal translocations result
in a fusion protein, whereby the N terminus of a transcription factor
is fused to an FGFR kinase domain, resulting in activation of FGFR ki-
nase domain [48–50]. At least 11 fusion partners of FGFR1 have been
identiﬁed including ZNF198 and BCR [49,50]. Most of the FGFR1 fu-
sion proteins are identiﬁed in patients with the myeloproliferative
disorder stem cell leukaemia/lymphoma syndrome (SCLL/8p11 mye-
loproliferative syndrome) [51]. These fusion proteins have been
shown to transform cells and induce SCLL in mice [49,52–55]. Recent
murine work has demonstrated that FGFR-targeted therapy using ty-
rosine kinase inhibitors may be beneﬁcial for patients with SCLL [54].
Multiple myelomas (MM) harbour the t(4;14) translocation in
15–20% of the cases. This translocation brings FGFR3 under the con-
trol of a strong IgH enhancer region, leading to FGFR3 overexpression
[56–58]. This translocation is associated with a poor prognosis in MM
and FGFR3 serves as an attractive therapeutic target. Several studies
using cell line and xenograft mouse models have provided a proof
of principle in the anti-tumour effects of small molecule FGFR3 inhib-
itors and of FGFR3 targeting antibodies [59–62].
3.2. FGFR overexpression and ampliﬁcation
Elevated levels of FGFR have been found in a number of cancers, in-
cludingprostate, breast, lung, brain, gastric, sarcoma, head andneck and
MM [57,63–70]. Elevated levels could be due to either deregulated tran-
scription or chromosomal ampliﬁcation. Despite evidence of upregu-
lated FGFR expression in different tumour types, it remains unclear
whether such abnormal receptor expression represents the underlying
molecular cause as a driver of cancer, or simply exists as a bystander, or
“passenger”, event within the overall mutational proﬁle of cancer.
Recent studies have demonstrated frequent focal ampliﬁcations of
FGFR1 in non-small cell lung carcinoma cell lines: 3% of lung adenocar-
cinomas and 21% of squamous cell carcinomas [71]. These cell lines are
dependent on FGFR1 activity for cell growth, since inhibition (with
shRNAs or small molecule inhibitors) of FGFR function leads to sup-
pressed cell growth. Interestingly, not all cell lines with FGFR1 ampliﬁ-
cation were sensitive to FGFR1 inhibition, which may reﬂect varying
phosphorylation status of FRS2, a required downstream effector for
FGFR [71]. Overall, in a panel of lung cancer cell lines (n=83), the
FGFR inhibitor PD1703074 potently inﬂuenced tumour growth and
survival.
FGFR1 is frequently upregulated in cancer of the prostate [71]. The
mechanism of this upregulation remains currently uncertain. The cur-
rent dogma suggests that FGFR1 upregulation acts to destroy theTable 2
Summary of genetic alterations in FGFRs and FGFs related to cancer.
Cancer Type Receptor and alteration References
Bladder FGFR3 mutation [70,104]
Breast FGFR1 and 2 ampliﬁcation [65,66,76–80,84,80,90]
FGFR2 and FGFR4 SNP
Endometrium FGFR2 mutation [97,101]
Gastric FGFR2 ampliﬁcation [73–75]
Multiple myeloma FGFR3 translocation [56–58]
Sarcoma FGFR4 mutation [127]subtle homeostatic interplay between epithelial and mesenchymal
cells [72]. Using a prostate-speciﬁc mouse model, Acevedo and col-
leagues targeted an inducible FGFR1 (iFGFR1) to the prostatic epithe-
lium [72]. Upon epithelial-speciﬁc activation of FGFR1, epithelial to
mesenchymal transition (EMT) and adenocarcinoma penetrant in all
cases were observed. Interestingly, deactivation of FGFR1 in the
early cancers leads to complete tumour regression, suggesting a role
of FGFR1 in both initiation and progression of prostate cancer.
When FGFR1 function was inactivated in late tumours in this model,
proliferation and progression of the tumours were impeded, but com-
plete tumour regression was not observed. This demonstrates differ-
ences in sensitivity to FGFR1 inhibition at different stages of
progression, indicating “susceptibility windows” [72]. This window
may be controlled by different signalling molecules, that may require
varying therapeutic targets [72].
Ampliﬁcation of FGFR1 and FGFR2 has been often described so far.
Approximately 10% of gastric cancers show FGFR2 upregulation,
which is associated with diffuse type cancer, often associated with a
poor prognosis [73,74]. In vitro studies using gastric cancer cells
with evidence of FGFR2 ampliﬁcation pointed to ligand-independent
signalling mechanisms, while paracrine effects of FGF7 further sup-
plemented cellular proliferation [67]. In a proportion of gastric cancer
cell lines, ampliﬁcation of FGFR2 can be accompanied by deletion of
the C-terminal exon that modulates receptor internalisation. The de-
letion results in expression of a truncated receptor variant. The conse-
quence of impaired receptor internalisation results in sustained
activation of the receptor [75].
Interestingly, a study by Kunii et al. identiﬁed a role for ampliﬁed
FGFR2 in gastric cancer cell proliferation and pro-survival effects in a
panel of cell lines [74]. Indeed FGFR2 kinase inhibition by a speciﬁc
small-molecule inhibitor (PD173074) resulted in selective and potent
growth arrest as well as prominent induction of apoptosis. Cell lines
harbouring FGFR2-ampliﬁcation also exhibited elevated phosphotyr-
osine levels in EGFR, Her2, and Erbb3. Intriguingly, this elevated
phosphorylation in EGFR was not inhibited by geﬁtinib or erlotinib
[74]. Instead, phosphotyrosine activation of EGFR, Her2, and ErbB3
depends on FGFR2 function, thus suggesting that EGFR family kinases
function as downstream targets of ampliﬁed FGFR2 in this model.
In 10% of human breast cancers, which is predominantly oestro-
gen receptor (ER) positive, there is an ampliﬁcation of the gene-rich
chromosomal region in 8p11-12, within which the FGFR1 gene is lo-
cated [76–78]. FGFR1 is not always overexpressed when this region
is ampliﬁed or it is not always contained in the ampliﬁcation
[79,80]. Nonetheless, it is evidenced in vitro that upregulation of
FGFR1 can drive mammary carcinogenesis, resulting in cellular trans-
formation of non-transformed murine/human mammary cells
[81–83]. Moreover, downregulation of FGFR1 in these mammary can-
cer cell lines results in cell death, indicating the oncogenic addition to
the FGFR1 upregulation [84]. Breast cancer cell lines harbouring
FGFR2 ampliﬁcation (SUM52PE and MFM-223) are well published
and sensitive to FGF inhibition [85]. This phenomenon occurs in ap-
proximately 2% of breast cancers. It has been found that breast and
gastric cancer cell lines harbouring FGFR2 ampliﬁcations predomi-
nantly express the IIIb isoform of the receptor. Thus FGFR2-IIIb-
speciﬁc antibodies (GP369) can suppress ligand-induced phosphory-
lation of FGFR2-IIIb and downstream signalling, as well as FGFR2-
driven proliferation both in vitro and in vivo [85].
FGFR1 ampliﬁcation is additionally reported in oral squamous car-
cinoma, ovarian cancer, bladder cancer and rhabdomyosarcoma
[64,86–88].
3.3. Point mutations and single-nucleotide polymorphisms
A recent screen of 210 different cancers found the FGF signalling
pathway was the most commonly mutated system amongst the
1000 somatic mutations found [92]. They found that the FGF
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suggesting that these are true “driver” mutations, driving tumour
growth and progression. A number of germ-line activating point mu-
tations of FGFR1, FGFR2, and FGFR3 found in human skeletal dyspla-
sias are also found in human cancers [93–95]. Mutated forms are
found in cancer of the prostate, bladder, breast, brain, lung, uterus,
stomach, head and neck, colon and malignant melanoma
[34,70,73,92,96–101].
Based on studies performed in FGFR3 mutant proteins, different
functional consequences of each point mutation in FGFRs can be sum-
marised as below [4]:
• Mutations in the extracellular domain of the receptor may facilitate
enhanced ligand binding or lead to an alteration of the ligand
speciﬁcity.
• Mutations in the ligand-binding and transmembrane domains can
induce dimerization of the receptor and thus increased or constitu-
tive activation.
• Mutations in the kinase domain may give rise to FGFRs with an in-
creased or constitutive activation.
• Mutations in the intracellular domain may result in impaired degra-
dation of the receptor, leading to continued signalling [102].
• Loss-of-function mutations have been also identiﬁed in cancer (see
Section 3.7) [103].
FGFR3 is one of the most commonly mutated genes in human
urothelial cell carcinoma (UCC) next to alterations in Chromosome
9 [104,105]. They are most prevalent in the low-grade non-muscle in-
vasive phenotype (50–60%), being less common in the high-grade
muscle-invasive subtype (10–15%). The somatic mutations found in
UCC match that of the germline activating mutations that cause
achondroplasia-type of skeletal dysplasia [70]. In UCC, more than
half of the mutations in FGFR3 occur in the ligand-binding domain
(S249C). The additional cysteine residue generated by the substitu-
tion is known to lead to the formation of an intra-molecular disul-
phide bridge, resulting in a constitutive dimerization and receptor
activation [106,107]. Mutations are also found in the transmembrane
domain (Y373C), which leads to an enhanced activation of the recep-
tor [107].
Mutations of the amino acid residue K652 in the kinase domain of
the FGFR3 are also found in UCC [108]. Crystal structures of FGFR2 ki-
nase domain indicated that the kinase domain mutation is likely to
allow the activation loop of the kinase domain to be in an active con-
formation and to indirectly disengage the auto-inhibition in the ki-
nase hinge region [109]. In cell line and xenograft studies of UCC,
the anti-FGFR3 antibodies and small molecule inhibitors showed
anti-tumour properties, suggesting that FGFR3 can be a potential
therapeutic target [59,110–114]. In contrast, the role of FGFR3 muta-
tions as a driver of UCC is still under debate. Mice with activating
Fgfr3 mutations displayed skin papilloma in two independent
models, indicating the role of FGFR3 in tumourigenesis [115,116].
However, our recent study introducing the Fgfr3 K644E mutation het-
erozygously (corresponding to human K652E mutation) in the
urothelium did not cause UCC [116]. However, a detailed analysis of
this model indicated an activation of negative feedback loops in
both Erk/MAPK and PI3K/Akt signalling cascade in a tissue-speciﬁc
fashion, suggesting a possibility that tumourigenesis in the bladder
requires additional mutations.
FGFR3 mutation has also been identiﬁed in cancer types such as
cervical cancer, MM, prostate cancer and spermatocytic seminomas
[96,117–120], as well as benign skin disorders epidermal naevi and
seborrhoeic kertosis [115,121,122].
Activating mutations of FGFR2 are found in approximately 10% of
endometrial/uterine cancers [97,101,125,126]. The mutations are
identical to those found in skeletal disorders such as Apert syndrome
(S252W and P253R which alter the ligand binding speciﬁcity) and
Crouzon syndrome (N549K and N659N which lead to ligandindependent receptor activation). In cell line and xenograft experi-
ments, inhibition/knockdown of FGFR2 resulted in anti-tumour ef-
fects, suggesting the oncogenic role of FGFR2 [97,124], raising the
potential of FGFR2 as a target of therapy in FGFR2 driven cancers.
Interestingly, in endometrial cancer, FGFR2 and K-Ras mutations
are mutually exclusive, suggesting redundancy and that only a single
‘hit’ is required to activate the MAPK signalling pathway [123,124].
Several mutations in FGFR4 have been identiﬁed in 7–8% of rhab-
domyosarcomas (RMS), associating with advanced stage and poor
survival [127,128]. The mutations occur in the auto-phosphorylation
sites of the receptor (N535K and V550E) and increase the ability to
invade and metastasise in both in vitro and in vivo studies [127].
SNPs of FGFR have also been identiﬁed in human cancers. Similar-
ly, the germline SNP in FGFR4 at nucleotide 388 correlates with a
higher resistance to chemotherapy in patients with breast cancer
[129]. In a mammary carcinoma model the FGFR4 G388R mutation
was found to promote cancer progression and metastasis [130]. This
may be because of impaired degradation compared to the wild type
receptor, resulting in sustained signalling. A SNP within intron 2 of
FGFR2 is associated with an increased risk of ER+ve breast cancer
[89,90]. It is speculated that the alteration of binding afﬁnity of two
transcription factors (Oct-1/Runx2 and C/EBPβ) causes an increase
in FGFR2 expression [66,91]. This increase in FGFR2 signalling due
to FGFR2 overexpression has demonstrated an anti-apoptotic effect.
3.4. Alternative splicing
The switch between alternatively spliced isoforms has been
shown to result in changes in FGFR signalling which promotes
tumourigenesis by the more oncogenic isoforms [75,131–133]. In
combination with altered ligand-binding speciﬁcity, this can result
further deregulation of FGFR-mediated signalling. Alternative splicing
of the third Ig-like domain confers the ligand binding speciﬁcity on
the receptor, with IIIb and IIIc being commonly associated with either
epithelial or mesenchymal cells. Interestingly the ligands for IIIb are
commonly expressed by the mesenchyme, whilst the IIIc ligands are
expressed by the epithelium. Thus this arrangement allows paracrine
signalling, but the switch of isoforms results in an autocrine-
signalling pattern. In rodent models of prostate and bladder cancer
this switch from FGFR2 IIIb to FGFR2 IIIc by alternative splicing results
in autocrine activation of FGFR2 and EMT [134–136]. However, it re-
mains unclear whether alternative splicing of the third Ig domain re-
sults in tumour promotion in humans. The Ittmann group reported
that alternative splicing of the third Ig domain of FGFR2 was rare in
human prostate cancer, and only occurred in a subgroup of patients
[63].
3.5. Impaired termination of signalling
Impaired termination of FGF signalling can contribute to tumour-
igenesis. A MAPK-dependent negative feedback loop via FRS2 is capa-
ble of regulating FGFR signalling [36]. It is believed that ERK1/2 may
phosphorylate FRS2 on multiple serine and/or threonine residues,
inhibiting the recruitment of Grb2 [36] to FRS2 can also be attenuated
by activation of the MAPK phosphatases, or by Sprouty and Sef pro-
teins [41–44].
In addition endocytosis and degradation of the receptor in lyso-
somes can terminate signalling in the physiologic context [47,137].
Disruptions of these pathways could lead to impaired signal termina-
tion and cellular transformation [138]. Mutation of the receptor can
render it insensitive to endocytosis, maintaining it at the cell surface.
Indeed, several mutations of the endocytic components have been
identiﬁed in cancer [139,140]. Mutations in Cbl, the ubiquitin ligase
that downregulates many RTKs are found to be mutated in acute my-
eloid leukaemia (AML), resulting in the accumulation of the RTK FLT3
[138]. Thus it would be interesting to investigate whether similar
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which are found in bladder, prostate and testicular cancer, have been
shown to be inefﬁciently degraded, resulting in active receptors with
twice the half-life of the wild type receptor [4].
Sef protein expression is decreased in breast, ovary, thyroid and
prostate tumours [141]. Sef has been shown to down-regulate FGF
signalling, and it is lost in high-grade and metastatic prostate cancer,
correlating with increased FGF2, FGF8, and FGFR4 [71,142,143]. Simi-
larly, the oncogenic splice variants of FGFR2 IIIb with deletion in its
COOH-terminal tail resulted in the loss of an endocytic signal se-
quence [75,131,132], leading to impaired receptor internalisation
and subsequently enhanced receptor signalling.
3.6. Increased autocrine or paracrine ligand stimulation of cancer growth
Most of the reported cases of genomic changes outlined so far af-
fect FGFR directly. Ligand-dependent signalling can also have an im-
portant role in pathogenesis of cancer, either via autocrine
(production of ligand by cancer cell) or paracrine pathways (pro-
duced by surrounding stroma, either at physiological levels or in re-
sponse to the abnormal cancer cell).
Elevated levels of FGF have been found in numerous cancers, fol-
lowed by validation of its oncogenic potentials in murine models. In-
creased levels of FGF2 have been identiﬁed in melanoma [144]. FGF2
is a potent angiogenic factor, and inhibition of FGF2 in human mela-
noma xenografts led to tumour regression and a reduction of tumour
angiogenesis [144]. Ampliﬁcation of FGF1 has been reported fre-
quently in ovarian cancer, and is associated with poor survival
[145]. FGF1 levels correlate with microvessel density, suggesting
that aberrantly expressed FGF1 functions in a paracrine manner, pro-
moting angiogenesis [145]. Elevated levels of FGF3, 4, and 8 have
been identiﬁed as mammary proto-oncogenes in MMTV-infected
mice, whilst FGF8 has been found to be upregulated in human breast
cancer [146–150]. Similarly, FGF8 is also upregulated in human pros-
tate cancer, and transgenic mice overexpressing FGF8 in prostatic ep-
ithelial cells develop PIN [151]. In a metastasis model, intra-tibial
injection of PC cells overexpressing FGF8 increased the tumour
incidence and size [152].
Hormonal FGFs, such as FGF19 are increased in the bloodstream of
some patients with cancer [153]. Transgenic mice overexpressing
FGF19 in the skeletal muscle developed hepatocellular carcinoma
(HCC), reﬂecting its endocrine action [154]. FGF19 is also overex-
pressed in a proportion of liver, colonic and lung squamous carcino-
mas. A monoclonal antibody that blocks FGF19 function has shown
anti-tumour effects on colonic cancer cells cultured in vitro and in
vivo as xenografts [153].
Murine studies have demonstrated the complex interplay be-
tween the epithelium and the mesenchyme in prostate cancer. They
have shown that mesenchymal overexpression of FGF10 was sufﬁ-
cient to induce epithelial transformation, resulting in the formation
of well differentiated prostatic adenocarcinomas [155].
Genetically, only a few mutations of FGF have been described in
humans. Six different somatic FGF9 mutations have been described
in colorectal and endometrial cancer [156]. Surprisingly these muta-
tions are predicted to have loss of FGF9 function, and it is still unclear
what role these may play in tumourigenesis.
An increase in the release of FGFs stored in ECM could also lead to
an increase in FGF signalling. FGFs have a high afﬁnity for heparan
sulphate proteoglycans (HSPGs), with most of the ligands stored in
the location nearby where they are produced to act as autocrine/para-
crine agents. FGFs can then be released by enzymatic cleavage of ex-
tracellular matrix [157]. Since cancer cells secrete proteases and
heparanases, which can directly lead to the release of sequestered
FGFs and increased FGF signalling [158].
Work by the Heasley lab (University of Colorado) has demonstrat-
ed the role of FGF2, FGF9 and their respective high-afﬁnity FGFRscompromise a growth factor autocrine loop that is active in a subset
of geﬁtinib-insensitive non-small cell lung cancer (NSCLC) cell lines
[69]. Similar results were demonstrated in head and neck squamous
cell carcinoma (HNSCC) cell lines. There was frequent co-expression
of FGF2 and FGFRs in HNSCC cell lines, instigating an autocrine loop
that either in isolation in collaboration with EGFR, drives cell growth
[159].
3.7. FGFR as a tumour suppressor gene
FGFRs have also been suggested to have tumour suppressor prop-
erties, since downregulated expression of FGFR2 in particular has
been found in many cancer subtypes.
Tumour-suppressive function of FGFRs has been suggested by the
example of FGFR2, where reduced FGFR2 expression has been
reported in several human cancer types including bladder, liver, sali-
vary gland and prostate [160–162]. In addition, loss-of-function mu-
tations in FGFR2 have been identiﬁed in melanoma [103,160–163].
Mice that speciﬁcally lack FGFR2-IIIb in keratinocytes are sensitised
to carcinogenic insults to their skin, developing an increased number
of papillomas and carcinomas compared to wild-type mice [164]. Ad-
ditionally, in a rat model of prostate cancer, when normal epithelial
cells expressing FGFR2-IIIb were mixed with stromal cells, benign tu-
mours were observed [135]. However, in the absence of stromal cells,
these epithelial cells expressing FGFR2-IIIb began expressing the IIIc
isoform. This elegant study demonstrated the crucial role for epitheli-
al–stromal interaction in the paracrine regulation of prostatic epithe-
lial cell proliferation [135]. Finally, the expression of FGFR2-IIIb was
shown to block proliferation in bladder cancer cell lines, [165],
while in bladder cancers (as well as prostate and salivary) this iso-
form is downregulated [163,166], indicating the tumour-suppressive
effect of FGFR2.
However it is far from clear that FGFR2 serves as a bona ﬁde tu-
mour suppressor, since it is also found to be upregulated in gastric,
pancreatic and breast cancer, as well as actively mutated in endome-
trial and lung cancer [97,100,101,167–169] (see Sections 3.2 and 3.3).
It is not well understood why it functions differently in different tu-
mour types. Although much interest has surrounded FGFR2-IIIb as
being tumour suppressive, with the IIIb isoform being potentially on-
cogenic, there is currently no evidence to suggest differential splicing
of the FGFR2 extracellular domain affects intracellular signalling.
Context-dependent variations in FGFR signalling may explain these
varying roles of FGFRs in human cancers.
4. FGFR as a target of therapy
Several FGFR tyrosine kinase inhibitors (TKIS) are currently in
phase I/II clinical trials [170–176]. All these inhibitors also inhibit
VEGFR, due to the high structural similarity of the kinase domains. Al-
though at ﬁrst it may beneﬁcial to inhibit both angiogenesis and pro-
liferation, many of these multiple targeting TKIs may be relatively less
potent as inhibitors against FGFRs. This also increases the side effect
proﬁle, limiting the deliverability of the drug at doses necessary for
inhibition of FGF signalling. AstraZeneca compound AZD4547 in a
dual FGFR1 and 2 inhibitor currently in phase 1 trials against advance
solid malignancies [177]. Similarly Novartis have 2 compounds in
their development pipeline. Dovitinib is an inhibitor of both VEGFR
and FGFRs in phase III development against renal cell carcinoma and
phase II development in advanced breast cancer, relapsed MM and
bladder cancer. Their other compound BGJ398 is a selective inhibitor
of FGFRs, with the phase I study currently on-going [178]. GP369, an
FGFR2-IIb-speciﬁc antibody has been used in vitro and in vivo to sup-
press the IIIb isoform in FGFR2 ampliﬁed human breast and gastric
cancer cell lines [86].
Thus, the ﬁeld is currently developing TKIs highly speciﬁc to FGFR.
As a proof-of-principle, pan-FGFR inhibitors have been demonstrated
856 I. Ahmad et al. / Biochimica et Biophysica Acta 1823 (2012) 850–860to be effective in PTEN null FGFR2 mutant cell lines [124]. Treatment
with the compound PD173074 resulted in cell death and cell cycle ar-
rest of endometrial cancer cell lines [124]. The effects correlate with
the inhibition of both FGFR1 and FGFR2 transphosphorylation. In a
small cell lung cancer model, PD173074 acts to impair cell prolifera-
tion both in cell lines and in xenograft tumours [179].
An alternative approach to TKIs is the FGF ligand traps which act
as FGF ‘sponges’, binding multiple FGFs, leading to both anti-
proliferative and anti-angiogenic effects such as the Five Prime drug
FP-1039 [180]. This has demonstrated efﬁcacy in a variety of preclin-
ical in vivo and in vitro models. Another approach involves the use of
FGFR blocking antibodies. Since antibodies are supposed to be speciﬁc
to particular FGFRs, they limit pan-FGFR inhibition toxicity. One of the
examples is the R3Mab antibody, which targets FGFR3, demonstrat-
ing anti-proliferative effects on xenografts of bladder cancer and
t(4;14) myeloma cells [59]. A ﬁnal approach utilises FGF ligands to
super stimulate FGFRs. A recombinant FGF7 ligand has been devel-
oped for use in mucostitis, induced by myelotoxic therapy [181].
5. Future perspectives
A plethora of reports from in vivo and in vitro human and animal
studies have demonstrated the potential role of FGFR signalling in
human carcinogenesis, whether it be in an oncogenic or tumour sup-
pressive capacity. It is still not well understood how FGFRs can act as
tumour suppressors, and this mechanism must be further elucidated
before we start to target FGFR as a therapeutic target in human dis-
eases. Indeed, up-regulating these tumour suppressor isoforms of
FGFR2 may provide an alternative strategy for pharmaceutical devel-
opments. It is also crucial that the tumours that are ‘driven’ by activa-
tion of FGF signalling are distinguished from those that merely have
FGF signalling as a ‘passenger’. In summary, it can be considered
that some tumours rely on deregulated FGF signalling on their devel-
opment and progression, and as such FGF signalling molecules pro-
vides an attractive target for treatment. This is promising since
multiple agents are now in the pipelines for preclinical and clinical
evaluation.
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